Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.57 |
| ▸ | GRM6 | O15303 | 2/20 | 0.57 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.57 |
| ▸ | GSR | P00390 | 2/20 | 0.57 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.57 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.57 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263150 | 1.00 | GRM8 (0.57) | GRM8GRM6GRM7GRM4SLC1A1 | |
| Succinic Acid SCHEMBL30975323 | 1.00 | GRM8 (0.57) | GRM8GRM6GRM7GRM4SLC1A1 | |
| SCHEMBL30670174 | 0.89 | GRM8 (0.53) | GRM8GRM6GRM7GRM4SLC1A1 | |
| SCHEMBL29714734 | 0.87 | BHMT (0.54) | GRM8GRM6GRM7GRM4SLC1A1 | |
| SCHEMBL11075958 | 0.85 | GRM8 (0.63) | GRM8GRM6GRM7GRM4SLC1A1 | |
| SCHEMBL21531606 | 0.82 | SLC1A1 (0.48) | GRM8GRM6GRM7GRM4SLC1A1 | |
| Glutamic Acid SCHEMBL19348257 | 0.80 | GRM8 (0.62) | GRM8GRM6GRM7GRM4SLC1A1 | |
| SCHEMBL7991509 | 0.80 | GRM8 (0.50) | GRM8GRM6GRM7GRM4SLC1A1 | |
| SCHEMBL7931451 | 0.78 | GRM8 (0.65) | GRM8GRM6GRM7GRM4SLC1A1 | |
| SCHEMBL6425120 | 0.78 | CYP2C19 (0.44) | GRM8GRM6GRM7GRM4SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021049876-A1 | METHOD FOR PRODUCING L-HOMOSERINE | 씨제이제일제당(주) | 2021-03-18 | — | — | WO | disclosed |
| US-9834491-B2 | Method for producing bio-based homoserine lactone and bio-based organic acid from O-acyl homoserine produced by microorganisms | CJ CHEILJEDANG CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9834491-B2 | Method for producing bio-based homoserine lactone and bio-based organic acid from O-acyl homoserine produced by microorganisms | CJ CHEILJEDANG CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-20140296466-A1 | Method for Producing Bio-Based Homoserine Lactone and Bio-Based Organic Acid from O-Acyl Homoserine Produced by Microorganisms | CJ CHEILJEDANG CORPORATION (KR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296466-A1 | Method for Producing Bio-Based Homoserine Lactone and Bio-Based Organic Acid from O-Acyl Homoserine Produced by Microorganisms | CJ CHEILJEDANG CORPORATION (KR) | 2014-10-02 | — | — | US | disclosed |
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2539333-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104266-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | GRM8 3858/4885GRM6 3010/4885GRM7 3691/4885 |
| US-20140296466-A1 | Method for Producing Bio-Based Homoserine Lactone and Bio-Based Organic Acid from O-Acyl Homoserine Produced by Microorganisms | HSD17B12, ABHD5, ACSL1 | GRM8 4065/4885GRM6 2018/4885GRM7 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.